News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
09 Jul 2026
byAudrey Abella
Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.








